{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:55:19Z","timestamp":1793044519735,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000106","name":"Saskatchewan Health Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000106","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.msard.2020.102028","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:43:06Z","timestamp":1582803786000},"page":"102028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Predictors of hospitalization in a Canadian MS population: A matched cohort study"],"prefix":"10.1016","volume":"41","author":[{"given":"Lina H","family":"Al-Sakran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1855-5595","authenticated-orcid":false,"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-0214","authenticated-orcid":false,"given":"Charity D","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102028_bib0001","series-title":"Handbook of Multiple Sclerosis","author":"Cohen","year":"2012"},{"issue":"8","key":"10.1016\/j.msard.2020.102028_bib0002","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1185\/03007995.2014.915802","article-title":"Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective us claims database analysis","volume":"30","author":"Bergvall N","year":"2014","journal-title":"Curr. Med. Res. Opin"},{"issue":"1","key":"10.1016\/j.msard.2020.102028_bib0003","first-page":"e11","article-title":"Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of ms patients in canada","volume":"19","author":"Karampampa K","year":"2012","journal-title":"J. Popul. Ther. Clin. Pharmacol"},{"key":"10.1016\/j.msard.2020.102028_bib0004","series-title":"Disorders and Injuries in Canada","article-title":"The burden of neurological diseases","year":"2007"},{"issue":"2","key":"10.1016\/j.msard.2020.102028_bib0005","first-page":"37","article-title":"Multiple sclerosis in canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts","volume":"37","author":"Amankwah","year":"2017","journal-title":"Chronic Dis. Inj. Can"},{"issue":"11","key":"10.1016\/j.msard.2020.102028_bib0006","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/00003246-199011000-00020","article-title":"National estimates of intensive care utilization and costs: canada and the united states","volume":"18","author":"Jacobs","year":"1990","journal-title":"Crit. Care Med."},{"issue":"1","key":"10.1016\/j.msard.2020.102028_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0195-668X(02)00384-6","article-title":"The use of hospital admission data as a measure of outcome in clinical studies of heart failure","volume":"24","author":"Metcalfe","year":"2003","journal-title":"Eur. Heart J"},{"issue":"11","key":"10.1016\/j.msard.2020.102028_bib0008","first-page":"735","article-title":"Hospital admissions and MS: temporal trends and patient characteristics","volume":"18","author":"Evans","year":"2012","journal-title":"Am. J. Manag. Care"},{"issue":"7","key":"10.1016\/j.msard.2020.102028_bib0009","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/MLR.0b013e31817a835d","article-title":"National health surveys and the behavioral model of health services use","volume":"46","author":"Andersen","year":"2008","journal-title":"Med. Care"},{"issue":"10","key":"10.1016\/j.msard.2020.102028_bib0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0000000000000753","article-title":"Dramatically changing rates and reasons for hospitalization in multiple sclerosis","volume":"83","author":"Marrie","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2020.102028_bib0011","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0b013e3181cf6ec0","article-title":"The rising prevalence and changing age distribution of multiple sclerosis in manitoba","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2020.102028_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005718","article-title":"The canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results","volume":"4","author":"Ploughman","year":"2014","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.msard.2020.102028_bib0013","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/pds.4207","article-title":"Adherence to disease\u2010modifying therapies for multiple sclerosis and subsequent hospitalizations","volume":"26","author":"Evans","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"10.1016\/j.msard.2020.102028_bib0014","author":"Canada","year":"2019","journal-title":"Saskatchewan Annual Population Report"},{"issue":"3","key":"10.1016\/j.msard.2020.102028_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/cjn.2017.301","article-title":"Establishing the incidence and prevalence of multiple sclerosis in saskatchewan","volume":"45","author":"Al-Sakran","year":"2018","journal-title":"Can. J. Neurol. Sci"},{"issue":"5","key":"10.1016\/j.msard.2020.102028_bib0016","first-page":"506","article-title":"Hypertension canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children","volume":"34","author":"Nerenberg","year":"2018","journal-title":"Can. J. Cardiol"},{"key":"10.1016\/j.msard.2020.102028_bib0017","volume":"3","author":"Rothman","year":"2008"},{"issue":"23","key":"10.1016\/j.msard.2020.102028_bib0018","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1212\/WNL.0000000000000495","article-title":"Intensive care unit admission in multiple sclerosis: increased incidence and increased mortality","volume":"82","author":"Marrie","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102028_bib0019","unstructured":"Canadian Institute for Health Information. Inpatient hospitalizations: volumes, length of stay, and standardized rates - Detailed Report b (Standardized rates). 2020; https:\/\/apps.cihi.ca\/mstrapp\/asp\/Main.aspx. Accessed 13 February 2020."},{"key":"10.1016\/j.msard.2020.102028_bib0020","unstructured":"Canadian Institute for Health Information. Trends in acute inpatient hospitalizations and day surgery visits in canada, 1995\u20131996 to 2005\u20132006. 2007; https:\/\/secure.cihi.ca\/free_products\/cad_analysis_in_brief_e.pdf. Accessed February 19, 2020."},{"issue":"7","key":"10.1016\/j.msard.2020.102028_bib0021","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.wnl.0000178891.20579.64","article-title":"Changes in the ascertainment of multiple sclerosis","volume":"65","author":"Marrie","year":"2005","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2020.102028_bib0022","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/1352458508089226","article-title":"Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada","volume":"14","author":"Warren","year":"2008","journal-title":"Multiple Sclerosis J"},{"issue":"4","key":"10.1016\/j.msard.2020.102028_bib0023","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1212\/WNL.0000000000001187","article-title":"Comorbidity increases the risk of hospitalizations in multiple sclerosis","volume":"84","author":"Marrie","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2020.102028_bib0024","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0735-1097(03)00947-1","article-title":"Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure","volume":"42","author":"Braunstein","year":"2003","journal-title":"J. Am. Coll. Cardiol"},{"issue":"4","key":"10.1016\/j.msard.2020.102028_bib0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00408-009-9222-y","article-title":"Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study","volume":"188","author":"Terzano","year":"2010","journal-title":"Lung"},{"issue":"24","key":"10.1016\/j.msard.2020.102028_bib0026","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1212\/WNL.0000000000004716","article-title":"Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study","volume":"89","author":"Kowalec","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2020.102028_bib0027","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.msard.2020.102028_bib0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2012.09.020","article-title":"Prognostic indicators for long-term disability in multiple sclerosis patients","volume":"324","author":"Damasceno","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"20","key":"10.1016\/j.msard.2020.102028_bib0029","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.msard.2020.102028_bib0030","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Multiple Sclerosis J"},{"issue":"4","key":"10.1016\/j.msard.2020.102028_bib0031","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/07853890.2018.1461919","article-title":"Adult hospital admissions associated with multiple sclerosis in finland in 2004\u20132014","volume":"50","author":"Pirttisalo","year":"2018","journal-title":"Ann. Med"},{"issue":"6","key":"10.1016\/j.msard.2020.102028_bib0032","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/NRL.0b013e31817533a3","article-title":"Central vertigo and dizziness: epidemiology, differential diagnosis, and common causes","volume":"14","author":"Karatas","year":"2008","journal-title":"Neurologist"},{"key":"10.1016\/j.msard.2020.102028_bib0033","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.msard.2019.03.012","article-title":"Thirty-day readmissions in multiple sclerosis: an age and gender-based us national retrospective analysis","volume":"31","author":"Patel","year":"2019","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"1","key":"10.1016\/j.msard.2020.102028_bib0034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12883-017-0932-0","article-title":"Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study","volume":"17","author":"Ragonese","year":"2017","journal-title":"BMC Neurol"},{"issue":"10","key":"10.1016\/j.msard.2020.102028_bib0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"issue":"Pt 10","key":"10.1016\/j.msard.2020.102028_bib0036","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from british columbia","volume":"135","author":"Kingwell","year":"2012","journal-title":"Canada Brain"},{"issue":"3","key":"10.1016\/j.msard.2020.102028_bib0037","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1352458514564489","article-title":"A systematic review of the incidence and prevalence of cancer in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Multiple Sclerosis J."},{"issue":"3","key":"10.1016\/j.msard.2020.102028_bib0038","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/bjc.2014.601","article-title":"Recurrent urinary tract infection and risk of bladder cancer in the nijmegen bladder cancer study","volume":"112","author":"Vermeulen","year":"2015","journal-title":"Br J. Cancer"},{"issue":"4","key":"10.1016\/j.msard.2020.102028_bib0039","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/oxfordjournals.aje.a113768","article-title":"Urinary tract infection and risk of bladder cancer","volume":"119","author":"Kantor","year":"1984","journal-title":"Am. J. Epidemiol."},{"issue":"7261","key":"10.1016\/j.msard.2020.102028_bib0040","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.321.7261.624","article-title":"ABC of breast diseases. breast cancer-epidemiology, risk factors, and genetics","volume":"321","author":"McPherson","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2020.102028_bib0041","doi-asserted-by":"crossref","first-page":"a2467","DOI":"10.1136\/bmj.a2467","article-title":"Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study","volume":"337","author":"Driver","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.msard.2020.102028_bib0042","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.0000000000001718","article-title":"Effect of comorbidity on mortality in multiple sclerosis","volume":"85","author":"Marrie","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2020.102028_bib0043","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458512437814","article-title":"Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia","volume":"18","author":"Marrie","year":"2012","journal-title":"Multiple Sclerosis J."},{"issue":"4","key":"10.1016\/j.msard.2020.102028_bib0044","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.msard.2013.03.001","article-title":"Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study","volume":"2","author":"Marrie","year":"2013","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2020.102028_bib0045","article-title":"Disparities in management and outcomes of myocardial infarction in multiple sclerosis: a matched cohort study","author":"Marrie","year":"2019","journal-title":"Multiple Sclerosis J."},{"issue":"3","key":"10.1016\/j.msard.2020.102028_bib0046","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1352458514564487","article-title":"The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review","volume":"21","author":"Marrie","year":"2015","journal-title":"Multiple Sclerosis J"},{"issue":"5","key":"10.1016\/j.msard.2020.102028_bib0047","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/09540261.2017.1322555","article-title":"Depression in multiple sclerosis","volume":"29","author":"Patten","year":"2017","journal-title":"Int. Rev. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2020.102028_bib0048","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000310301","article-title":"Socioeconomic trends in hospitalization for multiple sclerosis","volume":"35","author":"Lad","year":"2010","journal-title":"Neuroepidemiology"},{"issue":"11","key":"10.1016\/j.msard.2020.102028_bib0049","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1212\/01.WNL.0000095964.34294.B4","article-title":"Major depression in multiple sclerosis: a population-based perspective","volume":"61","author":"Patten","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102028_bib0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1352458508099477","article-title":"The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated","volume":"15","author":"Marrie","year":"2009","journal-title":"Multiple Sclerosis J"},{"issue":"9","key":"10.1016\/j.msard.2020.102028_bib0051","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2014.139","article-title":"The link between multiple sclerosis and depression","volume":"10","author":"Feinstein","year":"2014","journal-title":"Nat. Rev. Neurol"},{"issue":"7","key":"10.1016\/j.msard.2020.102028_bib0052","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00415-002-0725-0","article-title":"Multiple sclerosis, interferon beta-1b and depression a prospective investigation","volume":"249","author":"Feinstein","year":"2002","journal-title":"J. Neurol"},{"issue":"10","key":"10.1016\/j.msard.2020.102028_bib0053","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1007\/s00415-013-6979-y","article-title":"Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use","volume":"260","author":"O'Connor","year":"2013","journal-title":"J. Neurol"},{"issue":"11","key":"10.1016\/j.msard.2020.102028_bib0054","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1016\/j.clinthera.2015.09.011","article-title":"Relapses requiring intravenous steroid use and multiple-sclerosis-related hospitalizations: integrated analysis of the delayed-release dimethyl fumarate phase iii studies","volume":"37","author":"Giovannoni","year":"2015","journal-title":"Clin. Ther"},{"issue":"5","key":"10.1016\/j.msard.2020.102028_bib0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00415-011-6275-7","article-title":"Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting ms","volume":"259","author":"Weinstock-Guttman","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2020.102028_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033599","article-title":"Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study","volume":"9","author":"Al-Sakran","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.msard.2020.102028_bib0057","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pds.3667","article-title":"Association between beta-interferon exposure and hospital events in multiple sclerosis","volume":"23","author":"Evans","year":"2014","journal-title":"Pharmacoepidemiol. Drug. Saf"},{"issue":"1","key":"10.1016\/j.msard.2020.102028_bib0058","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv. Ther"},{"issue":"7","key":"10.1016\/j.msard.2020.102028_bib0059","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-008-0077-z","article-title":"Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients","volume":"25","author":"Castelli-Haley","year":"2008","journal-title":"Adv. Ther"},{"issue":"5","key":"10.1016\/j.msard.2020.102028_bib0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s12325-009-0028-3","article-title":"Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis","volume":"26","author":"Castelli-Haley","year":"2009","journal-title":"Adv. Ther"},{"issue":"6","key":"10.1016\/j.msard.2020.102028_bib0061","doi-asserted-by":"crossref","first-page":"469","DOI":"10.18553\/jmcp.2002.8.6.469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"Ollendorf","year":"2002","journal-title":"J. Managed Care Pharmacy"},{"issue":"5","key":"10.1016\/j.msard.2020.102028_bib0062","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01376517-200810000-00006","article-title":"Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis","volume":"40","author":"Ollendorf","year":"2008","journal-title":"J. Neurosci. Nurs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:23Z","timestamp":1761900563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820301048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":62,"alternative-id":["S2211034820301048"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102028","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of hospitalization in a Canadian MS population: A matched cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102028"}}